Related Experiment Videos
Efficacy of a WeChat mini-program-based self-management intervention for bipolar disorder: A randomized controlled
Xiaoling Lin1, Zhengling Ba2, Dali Lu3
1School of Nursing, Xiamen Medical College, Xiamen, 361023, China; School of Nursing, Sun Yat-sen University, Guangzhou, 510080, China.
Background:
Bipolar disorder (BD) often results in poor functional outcomes. Digital interventions offer a scalable solution, but evidence from China is scarce. This study evaluated the efficacy of "Mood Calm", a WeChat mini-program-based self-management intervention, for improving psychosocial functioning, quality of life (QoL), and clinical outcomes in BD.
Methods:
In this single-blind randomized controlled trial, 81 euthymic patients with BD were assigned to either WeChat mini-program "Mood Calm" intervention plus online group psychoeducation (n = 49) or a standard care control group (n = 32). Primary outcomes were psychosocial functioning and QoL. Secondary outcomes included mood symptoms, self-management ability, sleep, and physical activity. Assessments were conducted at baseline (T0), postintervention (T1, week 12), and at 12-week follow-up (T2, week 24).
Results:
No significant group × time interaction was found for psychosocial functioning. For QoL, the interaction did not reach the Bonferroni-corrected significance threshold (P = 0.033). In exploratory pairwise comparisons, the adjusted P value at T1 was 0.012, which does not provide confirmatory evidence of an intervention effect. For depressive symptoms, a significant interaction was identified (Bonferroni-corrected P = 0.019), although pairwise comparison at T1 did not survive Bonferroni adjustment. No significant interactions were observed for other outcomes.
Conclusions:
"Mood Calm" digital intervention demonstrated a significant interaction effect on depressive symptoms after Bonferroni correction, although between-group differences at individual time points were not confirmed in pairwise comparisons. Digital self-management tools may complement standard care, but further confirmatory research with larger samples is needed.
Trial Registration:
ChiCTR2200057901.